Want to see JP:177A full AI Analyst Report?
Top Page
Kohjin Bio Co.,Ltd.
(177A)
Select Model
Select Model
Rating:53Neutral
Price Target:
¥869.00
▼(-43.02% Downside)
Action:Reiterated
Date:07/09/26
The score is held back primarily by deteriorating financial performance—especially weaker profitability and negative free cash flow—and reinforced by bearish technicals with the stock trading below all major moving averages. A moderate P/E and modest dividend provide some valuation support, but they do not outweigh the near-term cash-flow and momentum risks.
Positive Factors
Improving Leverage
A falling debt-to-equity ratio meaningfully reduces financial risk and preserves financing flexibility. Over the next 2–6 months an improved leverage profile supports liquidity, lowers refinancing pressure, and gives management room to prioritize operations or strategic investments despite earnings softness.
Negative Factors
Negative Free Cash Flow
A material swing to negative free cash flow weakens funding autonomy and raises reliance on external financing or asset measures. Over 2–6 months this constrains reinvestment, increases balance-sheet vulnerability, and forces prioritization of cash conservation over growth or R&D activities.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Leverage
A falling debt-to-equity ratio meaningfully reduces financial risk and preserves financing flexibility. Over the next 2–6 months an improved leverage profile supports liquidity, lowers refinancing pressure, and gives management room to prioritize operations or strategic investments despite earnings softness.
Read all positive factors
Kohjin Bio Co.,Ltd. (177A) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥4.45B
Dividend Yield1.62%
Average Volume (3M)3.64K
Price to Earnings (P/E)17.5
Beta (1Y)0.75
Revenue Growth-5.13%
EPS Growth-68.42%
CountryJP
Employees176
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)49.05
Shares Outstanding5,111,600
10 Day Avg. Volume4,170
30 Day Avg. Volume3,643
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)1.04
Price to Sales (P/S)1.25
P/FCF Ratio-22.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)¥5.58B
Kohjin Bio Co.,Ltd. Business Overview & Revenue Model
Company Description
Kohjin Bio Co., Ltd., established in 1981 in Sakado, Japan, and known as Kohjin Co.,Ltd. until its rebranding in 1989, is a diversified life science enterprise. The company's core business involves the production and sale of various biological mat...
Kohjin Bio Co.,Ltd. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
71
Positive
Cash Flow
41
Neutral
| Breakdown | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.94B | 5.21B | 4.77B | 4.74B | 3.95B |
| Gross Profit | 1.86B | 2.37B | 1.88B | 2.45B | 2.04B |
| EBITDA | 766.46M | 1.41B | 958.10M | 1.44B | 1.14B |
| Net Income | 251.02M | 794.76M | 384.00M | 829.79M | 587.67M |
Balance Sheet | |||||
| Total Assets | 8.90B | 9.12B | 6.64B | 6.20B | 5.60B |
| Cash, Cash Equivalents and Short-Term Investments | 2.49B | 3.15B | 1.73B | 1.46B | 1.73B |
| Total Debt | 2.19B | 2.39B | 2.47B | 2.10B | 2.23B |
| Total Liabilities | 2.96B | 3.34B | 3.30B | 3.18B | 3.38B |
| Stockholders Equity | 5.95B | 5.78B | 3.34B | 3.02B | 2.22B |
Cash Flow | |||||
| Free Cash Flow | -280.78M | 28.05M | 260.88M | -99.57M | 559.44M |
| Operating Cash Flow | 698.51M | 915.55M | 823.68M | 461.15M | 762.98M |
| Investing Cash Flow | -867.67M | -1.09B | -577.35M | -575.46M | 82.78M |
| Financing Cash Flow | -320.76M | 1.38B | -1.35M | -172.21M | -360.17M |
Kohjin Bio Co.,Ltd. Technical Analysis
Negative
1525.00
Price Trends
1070.26
Negative
1164.34
Negative
1312.00
Negative
Market Momentum
-53.16
Negative
36.42
Neutral
70.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:177A, the sentiment is Negative. The current price of 1525 is above the 20-day moving average (MA) of 903.50, above the 50-day MA of 1070.26, and above the 200-day MA of 1312.00, indicating a bearish trend. The MACD of -53.16 indicates Negative momentum. The RSI at 36.42 is Neutral, neither overbought nor oversold. The STOCH value of 70.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:177A.
Kohjin Bio Co.,Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | ¥4.45B | 17.53 | ― | 1.62% | -5.13% | -68.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥26.52B | -34.31 | ― | ― | -11.11% | -187.80% | |
49 Neutral | ¥18.62B | -9.81 | ― | ― | ― | 6.10% | |
45 Neutral | ¥12.45B | -20.19 | ― | ― | -25.02% | -697.06% | |
42 Neutral | ¥8.81B | -7.90 | ― | ― | -62.06% | 7.56% |
* Healthcare Sector Average
JP:177A
Kohjin Bio Co.,Ltd.
860.00
-825.77
-48.98%
JP:4599
StemRIM Inc.
294.00
-7.00
-2.33%
JP:4978
ReproCELL Inc.
126.00
-72.00
-36.36%
JP:7774
Japan Tissue Engineering Co., Ltd.
621.00
-16.00
-2.51%
JP:7776
CellSeed Inc.
219.00
-255.00
-53.80%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.